<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Int Rep</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Int Rep</journal-id><journal-title-group><journal-title>Kidney International Reports</journal-title></journal-title-group><issn pub-type="epub">2468-0249</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29340315</article-id><article-id pub-id-type="pmc">5762947</article-id><article-id pub-id-type="publisher-id">S2468-0249(17)30344-3</article-id><article-id pub-id-type="doi">10.1016/j.ekir.2017.08.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Contrast-Induced Nephropathy and Oxygen Pretreatment in Patients With Impaired Renal Function</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sekiguchi</surname><given-names>Haruki</given-names></name><email>gucci_0418@yahoo.co.jp</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><on-behalf-of>for the Yokohama Medical Center Clinical Research Group</on-behalf-of><contrib contrib-type="author"><name><surname>Ajiro</surname><given-names>Yoichi</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Uchida</surname><given-names>Yoshie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Jujo</surname><given-names>Kentaro</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Iwade</surname><given-names>Kazunori</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Naohide</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Shimamoto</surname><given-names>Ken</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Tsurumi</surname><given-names>Yukio</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Kawana</surname><given-names>Masatoshi</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Hagiwara</surname><given-names>Nobuhisa</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>National Hospital Organization Yokohama Medical Center, Kanagawa, Japan</aff><aff id="aff2"><label>2</label>Aoyama Hospital Tokyo Women&#x02019;s Medical University, Tokyo, Japan</aff><aff id="aff3"><label>3</label>Tokyo Women&#x02019;s Medical University, Tokyo, Japan</aff><aff id="aff4"><label>4</label>You Heart Clinic, Tokyo, Tokyo, Japan</aff><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Correspondence:</bold> Haruki Sekiguchi, Department of Cardiology, Tokyo Women&#x02019;s Medical University, 8-1 Kawada-cho, Shinjyuku Ward, Tokyo, 162-8666, Japan.Department of CardiologyTokyo Women&#x02019;s Medical University8-1 Kawada-cho, Shinjyuku WardTokyo162-8666Japan <email>gucci_0418@yahoo.co.jp</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>8</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2017</year></pub-date><volume>3</volume><issue>1</issue><fpage>65</fpage><lpage>72</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>1</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 International Society of Nephrology. Published by Elsevier Inc.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>International Society of Nephrology</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Introduction</title><p>Contrast-induced nephropathy is a complication following coronary angiography and percutaneous coronary intervention. Because contrast-induced nephropathy is a predictor of long-term mortality in patients with ischemic heart disease undergoing percutaneous coronary intervention, preventive strategies are required. We assessed the effects of periprocedural oxygenation on contrast-induced nephropathy among patients with pre-existing renal dysfunction.</p></sec><sec><title>Methods</title><p>A total of 200 consecutive patients with impaired renal function (estimated glomerular filtration&#x000a0;&#x0003c; 60 ml/min per 1.73 m<sup>2</sup>) undergoing elective cardiovascular angiography were randomly assigned to an oxygenation treatment (n&#x000a0;= 100) or control group (n&#x000a0;= 100). In oxygenation treatment, pure oxygen (2 L/min) was administered for 10 minutes before exposure to contrast medium. The primary endpoint was the incidence of contrast-induced nephropathy, defined as a&#x000a0;&#x02265; 25% increase in serum creatinine levels from baseline within 48 hours of exposure.</p></sec><sec><title>Results</title><p>In the oxygenation treatment group, partial pressure of arterial oxygen was higher (135 &#x000b1; 25 mm&#x000a0;Hg vs. 84 &#x000b1; 10 mm&#x000a0;Hg, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001); contrast-induced nephropathy incidence was lower (1% vs. 8%, odds ratio [OR]&#x000a0;= 0.12, 95% confidence interval [CI]&#x000a0;= 0.01&#x02013;0.95, <italic>P</italic>&#x000a0;= 0.02); and partial pressure of arterial carbon dioxide and bicarbonate base lactate levels were similar compared with those in the control group. Upon univariate analysis, excess and absence of oxygenation treatment (OR&#x000a0;= 9.18, CI&#x000a0;= 1.13&#x02013;74.86, <italic>P</italic>&#x000a0;=&#x000a0;0.03) and anemia (OR&#x000a0;= 4.30, CI&#x000a0;= 1.04&#x02013;17.78, <italic>P</italic>&#x000a0;= 0.04) were shown to be associated with contrast-induced nephropathy incidence.</p></sec><sec><title>Conclusion</title><p>Oxygenation, a simple, nonpharmacological strategy, may be beneficial when using contrast media in patients with impaired renal function from noninvasive angiography to emergency catheterization.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>acute kidney injury</kwd><kwd>cardiovascular disease</kwd><kwd>chronic kidney disease</kwd><kwd>hypoxia</kwd><kwd>nephrotoxicity</kwd></kwd-group></article-meta></front><body><p id="p0010">Contrast-induced nephropathy (CIN), a complication following coronary angiography and percutaneous coronary intervention (PCI),<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> can progress to acute kidney injury and irreversible chronic kidney disease (CKD).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> CIN has been recognized as a significant predictor of long-term mortality in patients with ischemic heart disease who are undergoing PCI.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> Consequently, several preventive strategies have been developed; however, to date, only isotonic saline hydration has been accepted and applied as a standard preventive measure.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> CIN is caused by a combination of renal ischemia and direct toxic effects of contrast media on renal tubular cells.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> The renal medulla is uniquely susceptible to ischemic injury.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Contrast media may cause medullary hypoxia by shunting blood flow to the renal cortex.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> Although hydration exerts a degree of protection by maintaining renal plasma flow and improving intrarenal hypoxia, hydration alone is insufficient to prevent CIN, particularly in high-risk patients.</p><p id="p0015">A more effective approach toward CIN prevention may be achieved by combining isotonic saline hydration with oxygenation prior to contrast medium exposure. We recently reported the Option CIN study, showing that oxygenation treatment decreased CIN incidence in patients undergoing elective cardiac catheterization angiography.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The majority of patients enrolled in the Option CIN study had normal renal function; 122 of 349 patients (35%) had an estimated glomerular filtration rate (eGFR)&#x000a0;&#x0003c; 60/ml/min/1.73 m<sup>2</sup>. The incidence of CIN is widely recognized to be higher in patients with reduced eGFR.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Indeed, CIN occurred more frequently in patients with eGFR&#x000a0;&#x0003c; 60 ml/min/1.73 m<sup>2</sup> compared to those with eGFR&#x000a0;&#x02265; 60 ml/min/1.73 m<sup>2</sup> (6.5% vs. 0.8%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) in our previous study.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Moreover, renal damage from CIN is more severe in individuals with pre-existing impaired renal function than in those with normal renal function. Accordingly, we sought to determine whether oxygenation treatment is effective among patients with pre-existing renal dysfunction, who tend to have a higher incidence of CIN.</p><p id="p0020">Our proposed non-pharmacological preventive strategy using oxygen is safe, cost-saving, and widely applicable in either the elective or emergency setting for both outpatients and critically ill patients. The Extended-Option CIN study, a single-center, prospective, randomized controlled study, aimed to extend our previous findings to patients with reduced eGFR, a relatively high-risk subset of CIN, who underwent cardiac catheterization using contrast media.</p><sec id="sec1"><title>Materials and Methods</title><sec id="sec1.1"><title>Study Design</title><p id="p0025">The Option CIN study was a prospective open-label, randomized, single-center study of patients who underwent scheduled cardiovascular angiography, percutaneous coronary intervention (PCI), or both (n&#x000a0;=&#x000a0;349) from 29 April 2011 to 16 August 2011. The Extended-Option CIN study extended the recruitment period of the Option CIN study to evaluate the preventive effect of oxygenation on CIN in patients with impaired renal function, as a subpopulation analysis of the previous study. In the interim analysis of the previous study, 200 patients were enrolled (control group, n&#x000a0;= 100; oxygen group, n&#x000a0;=100). CIN occurred in 5 control-group patients and 1 treatment-group patient, all of whom demonstrated impaired renal function. Thus the rate of CIN among patients with impaired renal function was 14.7% (5 of 34) in the control group and 2.8% (1 of 36) in the treatment group. In the present study, sample size calculation was conducted based on this interim analysis using a CIN incidence of 2.8% in the oxygenation treatment group and 14.7% in the control group. To detect a difference in CIN incidence between the 2 groups using the Fisher exact probability test at a power of 80%, &#x003b1; error of 0.5 (2-sided), and &#x003b2; error of 0.05, we calculated that 89 patients per control group and treatment group would need to be enrolled. Factoring in a 10% dropout rate, we estimated that 98 patients were needed per group. Therefore, we enrolled and evaluated 200 new patients with impaired renal function in the present study.</p></sec><sec id="sec1.2"><title>Study Population</title><p id="p0030">Between 1 September 2011 and 30 June 2012, a total of&#x000a0;200 consecutive patients with an eGFR&#x000a0;&#x0003c; 60 ml/min/1.73 m<sup>2</sup> (mean, 48.4 &#x000b1; 9.3 ml/min/1.73 m<sup>2</sup>, range 18.4&#x02013;59.9 ml/min/1.73 m<sup>2</sup>) who underwent elective cardiovascular angiography, PCI, or both were enrolled. Exclusion criteria were acute coronary syndrome, end-stage renal failure requiring dialysis, cardiogenic shock, symptomatic and congestive heart failure, pregnancy, a history of hypersensitivity to contrast media, metformin ingestion within 48 hours of study entry, chronic obstructive pulmonary disease, oxygen saturation level&#x000a0;&#x0003c;90% (indicating respiratory failure, necessitating a supply of oxygen), use of an antioxidant drug such as <italic>N</italic>-acetylcysteine to prevent CIN, severe infection, and severe malnutrition. Patients in whom CIN occurred were followed up in terms of clinical outcomes and renal function for 1 month after the procedure, with some followed up for as long as 1 year.</p></sec><sec id="sec1.3"><title>Study Protocol</title><p id="p0035">Eligible patients were randomly assigned in a 1:1 ratio to receive either supplemental oxygen (oxygenation treatment group) or room air (control group). All patients received i.v. hydration with 0.9% isotonic saline at a rate of 1 ml/kg per hour (or 0.5 ml/kg per hour in cases with an ejection fraction&#x000a0;&#x0003c; 40%) for 12 hours before and after the procedure as a standard preventive measure. Randomization of patients was performed by a computer in blocks of 4. Groups were sequentially assigned by a research pharmacist who dispensed medications but was not otherwise involved in the study.</p><p id="p0040">Blood oxygenation levels were assessed using arterial blood gas samples obtained before and after the procedure through an arterial sheath. Serum creatinine and blood urea nitrogen levels were measured before angiography (during hydration before contrast) and 48 hours after the procedure to determine the development of CIN. Catheterization was performed via the radial artery, or the femoral artery in difficult cases, without sedation. Low osmolality, non-ionic contrast agent iopamidol (Iopamiron, Osaka, Japan) was used. The eGFR was calculated using a level-modified Japanese adaptation of the Modification of Diet in Renal Disease formula<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>: eGFR in men&#x000a0;= 0.741&#x000a0;&#x000d7; 175&#x000a0;&#x000d7; (age in years) <sup>&#x02212; 0.203</sup>&#x000a0;&#x000d7; (serum creatinine in mg/dl) <sup>&#x02212; 1.154</sup>, and eGFR in women&#x000a0;= (eGFR in men)&#x000a0;&#x000d7; 0.742. The primary endpoint of the study was CIN incidence. Athough CIN has also been defined as an increase in the absolute creatinine level by 44 &#x003bc;mol/l (0.5 mg/dl) from baseline, for the purpose of this study, CIN was defined as an increase in serum creatinine levels of&#x000a0;&#x02265; 25% from baseline within 48 hours of contrast medium administration. We also evaluated the occurrence of acute kidney injury, defined as an increase in serum creatinine of &#x0003e; 0.3 mg/dl compared to baseline within 48 hours, and sustained kidney injury defined was as eGFR reduction of &#x0003e; 30% for 6 to 12 months after the procedure.</p></sec><sec id="sec1.4"><title>Oxygenation Treatment</title><p id="p0045">In the oxygenation treatment group, patients received 2 L/min of pure oxygen intranasally from 10 minutes prior to contrast medium exposure until the end of the procedure. Oxygen administration was terminated at the end of the procedure. In addition, our previous study showed that a low partial pressure of arterial oxygen (PaO<sub>2</sub>) (&#x0003c; 100 mm&#x000a0;Hg) was significantly associated with a high incidence of CIN. Therefore, the present study sought to determine the efficacy of oxygen administration at a concentration of 2 L/min, which is sufficient to increase the PaO<sub>2</sub> levels &#x0003e; 100 mm&#x000a0;Hg in most stable patients. Administration commenced 10 minutes prior to contrast medium exposure because oxygen levels usually plateau within 3 to 10 minutes of oxygenation.</p></sec><sec id="sec1.5"><title>Statistical Analysis</title><p id="p0050">All continuous data were analyzed using the <italic>t</italic> test (a paired <italic>t</italic> test for before-and-after comparison within a single group, and an unpaired <italic>t</italic> test for comparisons between experimental groups), or using the Mann&#x02013;Whitney <italic>U</italic> test or Wilcoxon signed-rank test if data were skewed. Categorical data were compared using the &#x003c7;<sup>2</sup> test or Fisher exact test. We referred to 2 risk score models. In a report by Morcos <italic>et&#x000a0;al.</italic>, CIN occurred in 10% to 30% of participants with risk factors, and in a study by Rich <italic>et&#x000a0;al.</italic>, CIN occurred in patients with high serum creatinine (&#x0003e; 1.5 mg/dl), high contrast volume (&#x0003e; 200 ml), diabetes, low serum albumin (&#x0003c; 3.5 g/dl), or hyponatremia (&#x0003c; 135 mM). CIN predictors such as sex, age &#x0003e; 70 years, hypertension, diabetes mellitus, dyslipidemia, history of myocardial infarction, brain natriuretic peptide &#x0003e; 100 pg/dl, anemia, use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, or statins, contrast media &#x0003e; 150 ml, and oxygenation treatment were first evaluated using logistic regression.</p><p id="p0055">All statistical analyses were performed using SPSS statistical software (version 17.0,; SPSS Institute, Chicago, IL). <italic>P</italic> values&#x000a0;&#x0003c; 0.05 were considered statistically significant. Continuous data are reported as mean &#x000b1;&#x000a0;SD, skewed variables as median and interquartile range, and categorical data as absolute values and percentages.</p></sec><sec id="sec1.6"><title>Ethical Considerations</title><p id="p0060">The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The ethics committee of our institution approved the study protocol (NHO11-11), and written informed consent was obtained from all patients before study entry.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Patient Demographics</title><p id="p0065">A total of 200 participants were enrolled in the study, with a mean eGFR of 48.4 &#x000b1; 9.3 ml/min per 1.73 m<sup>2</sup> (range, 18.4&#x02013;59.9 ml/min per 1.73 m<sup>2</sup>). The patients&#x02019; mean age was 74.2 &#x000b1; 8.2 years, and 77% (153 of 200) were &#x0003e; 70 years of age. <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> presents the patients&#x02019; baseline characteristics. Pre-existing renal dysfunction, diabetes mellitus, and heart failure are possible risk factors for CIN.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> However, no significant differences were observed between groups in terms of indices related to these risk factors or with regard to other factors such as baseline eGFR, cystatin C, creatinine, blood urea nitrogen, hemoglobin A1c (HbA1c), and brain natriuretic peptide levels. In addition, the proportion of patients receiving calcium channel blockers, &#x003b2;-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, or statins was equivalent between groups. The volume of contrast medium and procedure duration in the oxygenation treatment group were equivalent to those in the control group (109 &#x000b1; 48 ml vs. 110 &#x000b1; 56 ml, <italic>P</italic>&#x000a0;=&#x000a0;0.89, and 47 &#x000b1; 35 minutes vs. 48 &#x000b1; 34 minutes, <italic>P</italic>&#x000a0;= 0.84, respectively) (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).<table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of study patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical characteristics</th><th>Oxygenation treatment (n&#x000a0;= 100)</th><th>Control (n&#x000a0;= 100)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Age, yr</td><td>73.8 &#x000b1; 8.3</td><td>74.6 &#x000b1; 8.1</td><td align="char">0.49</td></tr><tr><td>Male sex, n (%)</td><td>66 (66.0%)</td><td>64 (64.0%)</td><td align="char">0.77</td></tr><tr><td>Body mass index</td><td>23.1 &#x000b1; 4.0</td><td>24.0 &#x000b1; 4.1</td><td align="char">0.12</td></tr><tr><td>Diabetes, n (%)</td><td>30 (30.0%)</td><td>38 (38.0%)</td><td align="char">0.23</td></tr><tr><td>Hypertension, n (%)</td><td>85 (85.0%)</td><td>86 (86.0%)</td><td align="char">0.84</td></tr><tr><td>Dyslipidemia, n (%)</td><td>63 (63.0%)</td><td>66 (66.0%)</td><td align="char">0.66</td></tr><tr><td>Current smoking, n (%)</td><td>6 (6.0%)</td><td>6 (6.0%)</td><td align="char">1.00</td></tr><tr><td>Prior CABG, n (%)</td><td>4 (4.0%)</td><td>4 (4.0%)</td><td align="char">1.00</td></tr><tr><td>Prior PCI, n (%)</td><td>27 (27.0%)</td><td>31 (31.0%)</td><td align="char">0.53</td></tr><tr><td>History of myocardial infarction, n (%)</td><td>15 (15.0%)</td><td>19 (19.0%)</td><td align="char">0.45</td></tr><tr><td>Volume of contrast medium (ml)</td><td>109 &#x000b1; 48</td><td>110 &#x000b1; 56</td><td align="char">0.89</td></tr><tr><td>Procedure time (min)</td><td>47 &#x000b1; 35</td><td>48 &#x000b1; 34</td><td align="char">0.84</td></tr><tr><td>Medications</td><td/><td/><td/></tr><tr><td>ACE inhibitors, n (%)</td><td>9 (9.0%)</td><td>10 (10.0%)</td><td align="char">0.81</td></tr><tr><td>Angiotensin II receptor inhibitors, n (%)</td><td>49 (49.0%)</td><td>54 (54.0%)</td><td align="char">0.48</td></tr><tr><td>Calcium channel blocker, n (%)</td><td>31 (31.0%)</td><td>38 (38.0%)</td><td align="char">0.29</td></tr><tr><td>&#x003b2;-Blockers</td><td>36 (36.0%)</td><td>34 (34.7%)</td><td align="char">0.77</td></tr><tr><td>Aspirin, n (%)</td><td>59 (59.0%)</td><td>60 (60.0%)</td><td align="char">0.89</td></tr><tr><td>Statins, n (%)</td><td>49 (49.0%)</td><td>53 (53.0%)</td><td align="char">0.57</td></tr><tr><td>Diuretics, n (%)</td><td>35 (35.0%)</td><td>37 (37.0%)</td><td align="char">0.77</td></tr><tr><td>Laboratory tests</td><td/><td/><td/></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.08 &#x000b1; 0.21</td><td>1.08 &#x000b1; 0.25</td><td align="char">1.00</td></tr><tr><td>Cystatin C (mg/dl)</td><td>1.11 &#x000b1; 0.32</td><td>1.13 &#x000b1; 0.27</td><td align="char">0.63</td></tr><tr><td>eGFR (ml/min per 1.73 m<sup>2</sup>)</td><td>48.4 &#x000b1; 9.1</td><td>48.6 &#x000b1; 9.0</td><td align="char">0.88</td></tr><tr><td>eGFR 30&#x02013;60 (%)</td><td>95 (95.0%)</td><td>96 (96.0%)</td><td align="char">0.73</td></tr><tr><td>eGFR&#x000a0;&#x0003c; 30 (%)</td><td>5 (5.0%)</td><td>4 (4.0%)</td><td align="char">0.73</td></tr><tr><td>Blood urea nitrogen (mg/dl)</td><td>19.6 &#x000b1; 5.9</td><td>19.4 &#x000b1; 6.8</td><td align="char">0.82</td></tr><tr><td>HbA1c (%)</td><td>6.2 &#x000b1; 3.7</td><td>5.9 &#x000b1; 1.0</td><td align="char">0.43</td></tr><tr><td>BNP (ng/ml)</td><td>211.7 &#x000b1; 315.5</td><td>167.5 &#x000b1; 332.2</td><td align="char">0.34</td></tr><tr><td>Procedure</td><td/><td/><td/></tr><tr><td>Coronary artery angiography</td><td>78 (78%)</td><td>78 (78%)</td><td align="char">1.00</td></tr><tr><td>PCI</td><td>22 (22%)</td><td>22 (22%)</td><td align="char">1.00</td></tr><tr><td>Mehran&#x02019;s risk score</td><td>7.6 &#x000b1; 3.1</td><td>7.0 &#x000b1; 3.4</td><td align="char">0.19</td></tr></tbody></table><table-wrap-foot><fn><p>ACE, angiotensin-converting enzyme; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.2"><title>Effects of Oxygenation Treatment on CIN Incidence</title><p id="p0070">As presented in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, the initial arterial blood gas levels were significantly higher in the oxygenation treatment group than in the control group (135 &#x000b1; 25 mm&#x000a0;Hg vs. 84 &#x000b1; 10 mm&#x000a0;Hg, <italic>P</italic>&#x000a0;&#x0003c; 0.001). The total duration of oxygenation in the oxygenation treatment group was 62 &#x000b1; 35 minutes. No statistically significant difference was observed in the levels of partial pressure of arterial carbon dioxide (PCO<sub>2</sub>), bicarbonate (HCO<sub>3</sub><sup>&#x02212;</sup>), base excess, or lactate between groups. Therefore, systemically higher PaO<sub>2</sub> levels in the arterial blood were achieved prior to contrast medium administration at oxygen levels of 2 L/min.<table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Comparison of preprocedural arterial blood gas between the patients in the oxygenation treatment and the control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Oxygenation treatment (n&#x000a0;= 100)</th><th>Control Group (n&#x000a0;= 100)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>pH</td><td align="char">7.416 &#x000b1; 0.061</td><td align="char">7.418 &#x000b1; 0.039</td><td align="char">0.78</td></tr><tr><td>PaO<sub>2</sub> (mm&#x000a0;Hg)</td><td align="char">134.5 &#x000b1; 25.2</td><td align="char">83.8 &#x000b1; 10.0</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>PaCO<sub>2</sub> (mm&#x000a0;Hg)</td><td align="char">38.2 &#x000b1; 5.6</td><td align="char">39.5 &#x000b1; 5.2</td><td align="char">0.09</td></tr><tr><td>HCO<sub>3</sub><sup>&#x02212;</sup> (mEq/L)</td><td align="char">24.0 &#x000b1; 2.9</td><td align="char">24.8 &#x000b1; 3.0</td><td align="char">0.06</td></tr><tr><td>Base excess (mEq/L)</td><td align="char">0.3 &#x000b1; 2.6</td><td align="char">0.4 &#x000b1; 2.8</td><td align="char">0.79</td></tr><tr><td>Hemoglobin (mg/dl)</td><td align="char">12.3 &#x000b1; 1.8</td><td align="char">12.5 &#x000b1; 1.9</td><td align="char">0.45</td></tr><tr><td>Hematocrit (%)</td><td align="char">36.6 &#x000b1; 4.8</td><td align="char">37.1 &#x000b1; 5.4</td><td align="char">0.49</td></tr><tr><td>Na (mEq/L)</td><td align="char">139.7 &#x000b1; 2.8</td><td align="char">139.6 &#x000b1; 2.8</td><td align="char">0.80</td></tr><tr><td>K (mEq/L)</td><td align="char">4.3 &#x000b1; 0.4</td><td align="char">4.3 &#x000b1; 0.5</td><td align="char">1.00</td></tr><tr><td>Cl (mEq/L)</td><td align="char">106.3 &#x000b1; 3.9</td><td align="char">105.9 &#x000b1; 3.9</td><td align="char">0.47</td></tr><tr><td>Lactate (mg/dl)</td><td align="char">8.1 &#x000b1; 2.5</td><td align="char">7.9 &#x000b1; 2.5</td><td align="char">0.57</td></tr></tbody></table><table-wrap-foot><fn><p>HCO<sub>3</sub><sup>&#x02212;</sup>, bicarbonate; Pa0<sub>2</sub>, partial pressure of arterial oxygen.</p></fn></table-wrap-foot></table-wrap></p><p id="p0075">Overall, CIN developed in 9 patients (4.5%). CIN incidence was significantly lower in the oxygenation treatment group than in the control group (1 of 100 [1%] vs. 8 of 100 [8%]; odds ratio [OR]&#x000a0;= 0.12, 95% confidence interval [CI]&#x000a0;= 0.01&#x02013;0.95, <italic>P</italic>&#x000a0;= 0.02) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>a). However, there was no difference in CIN incidence between the 2 groups, when the definition of CIN was an increase in the serum creatinine level 0.5 mg/dl above baseline. Serum creatinine levels increased in the control group (<italic>P</italic>&#x000a0;= 0.04) but remained unchanged in the oxygenation treatment group (<italic>P</italic>&#x000a0;=&#x000a0;0.714) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>b). Moreover, the mean change in serum creatinine levels was lower in the oxygenation treatment group (&#x02212;0.01 &#x000b1; 0.12 mg/dl) than in the control group (0.07 &#x000b1; 0.24 mg/dl; <italic>P</italic>&#x000a0;&#x0003c; 0.001) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>c). Similarly, the baseline eGFR was equivalent between groups.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>(a) Contrast-induced nephropathy (CIN) incidence between study groups. CIN incidence was significantly lower in the oxygenation treatment group than in the control group (1/100 [1%] vs. 8/100 [8%], odds ratio&#x000a0;= 0.12, 95% confidence interval&#x000a0;= 0.01&#x02013;0.95, <italic>P</italic>&#x000a0;= 0.02). (b) Changes in serum creatinine levels following contrast exposure. Postprocedural serum creatinine levels increased in the control group (1.08 &#x000b1; 0.25 mg/dl to 1.15 &#x000b1; 0.31 mg/dl, <italic>P</italic>&#x000a0;= 0.04) but remained unchanged in the oxygenation treatment group (1.08 &#x000b1; 0.21 mg/dl to 1.07 &#x000b1; 0.19 mg/dl, <italic>P</italic>&#x000a0;= 0.714). (c) Median and interquartile range of serum creatinine levels before and after cardiovascular angiography. The average change in serum creatinine levels was significantly lower in the oxygenation treatment group than in the control group (&#x02212;0.01 &#x000b1; 0.12 mg/dl vs. 0.07 &#x000b1; 0.24 mg/dl, <italic>P</italic>&#x000a0;&#x0003c; 0.001). Data are presented as mean &#x000b1; SD. NS, not significant.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0080">The occurrence of acute kidney injury was also lower in the oxygenation treatment group than in the control group (1 of 100 [1%] vs. 11 of 100 [11%]; OR&#x000a0;=&#x000a0;0.08, 95% CI&#x000a0;= 0.01&#x02013;0.65, <italic>P</italic>&#x000a0;= 0.0029).</p></sec><sec id="sec2.3"><title>Risk for CIN</title><p id="p0085">In the univariate analysis, 2 factors were significantly associated with a higher CIN incidence: no oxygenation treatment (OR&#x000a0;= 9.18, 95% CI&#x000a0;= 1.13&#x02013;74.86, <italic>P</italic>&#x000a0;&#x0003c; 0.05) and anemia, defined as a hemoglobin level&#x000a0;&#x0003c; 12.0 mg/dl in men and&#x000a0;&#x0003c; 11.0 mg/dl in women (OR&#x000a0;= 4.30, 95% CI&#x000a0;= 1.04&#x02013;17.78, <italic>P</italic>&#x000a0;&#x0003c; 0.05). However, diabetes mellitus, the volume of contrast medium (&#x02265; 150 ml), hypertension, brain natriuretic peptide level &#x0003e; 100 pg/dl, and medication use (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins, and diuretics) were not associated with CIN incidence in this study population (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>).<table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Univariate analysis for the occurrence of contrast-induced nephropathy (CIN)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">CIN<hr/></th><th rowspan="2">OR</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>+ (n&#x000a0;= 9)</th><th>&#x02212; (n&#x000a0;= 191)</th></tr></thead><tbody><tr><td>Male</td><td align="char">6 (66.7%)</td><td align="char">124 (64.9%)</td><td align="char">1.08</td><td align="char">0.92</td></tr><tr><td>Age &#x0003e; 70 yr</td><td align="char">7 (77.8%)</td><td align="char">146 (76.4%)</td><td align="char">1.08</td><td align="char">0.93</td></tr><tr><td>Hypertension</td><td align="char">8 (88.9%)</td><td align="char">156 (81.6%)</td><td align="char">1.79</td><td align="char">0.58</td></tr><tr><td>Diabetes mellitus</td><td align="char">2 (22.2%)</td><td align="char">68 (35.6%)</td><td align="char">0.52</td><td align="char">0.41</td></tr><tr><td>Dyslipidemia</td><td align="char">6 (66.7%)</td><td align="char">127 (66.5%)</td><td align="char">1.01</td><td align="char">0.99</td></tr><tr><td>History of myocardial infarction</td><td align="char">0 (0.0%)</td><td align="char">34 (17.8%)</td><td align="char">0.24</td><td align="char">0.16</td></tr><tr><td>BNP &#x0003e; 100 pg/dl</td><td align="char">6 (66.7%)</td><td align="char">67 (35.1%)</td><td align="char">3.70</td><td align="char">0.05</td></tr><tr><td>Anemia<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td align="char">6 (66.7%)</td><td align="char">60 (20.1%)</td><td align="char">4.37</td><td align="char">0.03</td></tr><tr><td>ACE inhibitors or ARBs</td><td align="char">4 (44.4%)</td><td align="char">118 (61.8%)</td><td align="char">0.49</td><td align="char">0.30</td></tr><tr><td>Diuretics</td><td align="char">4 (44.4%)</td><td align="char">68 (35.6%)</td><td align="char">1.45</td><td align="char">0.59</td></tr><tr><td>Statins</td><td align="char">4 (44.4%)</td><td align="char">98 (51.3%)</td><td align="char">0.76</td><td align="char">0.69</td></tr><tr><td>Contrast media &#x0003e; 150 ml</td><td align="char">3 (33.3%)</td><td align="char">26 (13.6%)</td><td align="char">3.17</td><td align="char">0.10</td></tr><tr><td>No oxygenation treatment</td><td align="char">8 (88.9%)</td><td align="char">92 (48.1%)</td><td align="char">8.61</td><td align="char">0.02</td></tr></tbody></table><table-wrap-foot><fn><p>ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; OR, odds ratio.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0010">Anemia was defined as a hemoglobin concentration of&#x000a0;&#x0003c; 12 mg/dl for men or&#x000a0;&#x0003c; 11 mg/dl for women.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.4"><title>Follow-up of Patients With CIN</title><p id="p0090">Over the course of this study, no patient died, and none developed end-stage kidney disease requiring dialysis. The rate of patients with 30% eGFR reduction at 6 to 12 months after the procedure was significantly lower in the oxygenation treatment group (10%) compared to the control group (21%) (OR&#x000a0;= 2.37, 95% CI&#x000a0;= 1.05&#x02013;5.33, <italic>P</italic>&#x000a0;= 0.034).</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0095">Our study findings indicated that the addition of oxygenation treatment to standard hydration decreased the CIN incidence in patients with reduced eGFR undergoing cardiovascular angiography. Therefore, oxygenation treatment may protect against CIN in patients with impaired renal function during the scheduled cardiovascular angiography.</p><p id="p0100">CIN occurs at an incidence of 10% to 30%, inclusive of patients with pre-existing renal dysfunction or diabetes mellitus, in whom a standard hydration protocol is not administered.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib14" ref-type="bibr">14</xref> In patients without these risk factors, the CIN incidence decreases to approximately 3.3% following coronary angiography. Although several preventive strategies have been identified and investigated, a definitive solution remains to be established.</p><p id="p0105">The pathogenesis of CIN is not fully understood, and&#x000a0;little is known regarding cellular mechanisms underlying this condition.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> To date, contrast medium&#x02212;induced direct tubular and mesangial toxicity,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> intraluminal obstruction,<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and immunological injury<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> have been explored. Renal hypoxia<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> and the concomitant release of reactive oxygen are also considered important mechanisms of renal injury following contrast medium administration.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Thus, CIN is currently believed to result from renal damage caused by a combination of both direct toxicity of contrast agents and renal ischemia associated with reduced renal blood flow.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p><p id="p0110">Liss <italic>et&#x000a0;al.</italic> demonstrated that contrast medium administration decreased oxygen tension in the renal medulla 10 minutes after injection, and caused renal parenchymal PaO<sub>2</sub> levels to decline to critically low levels (&#x0223c;10 mm&#x000a0;Hg) within medullary structures extending to the renal cortex.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Therefore, because of the relationship between systematic oxygenation and contrast media exposure described by Heyman <italic>et&#x000a0;al.</italic>,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> we thought that oxygen administration might prevent this drop in inner medullary oxygen.</p><p id="p0115">Interestingly, a reduction of approximately 5% in systemic PaO<sub>2</sub> levels was observed after the procedure in both groups in the present study. This decrease was statistically significant only in the control group following angiographic procedures (135 &#x000b1; 25 mm&#x000a0;Hg to 130 &#x000b1; 47 mm&#x000a0;Hg in the oxygenation treatment group, <italic>P</italic>&#x000a0;= 0.35; 84 &#x000b1; 10 mm&#x000a0;Hg to 80 &#x000b1; 10 mm&#x000a0;Hg in the control group, <italic>P</italic>&#x000a0;&#x0003c; 0.01), suggesting that renal hypoxia was additively enhanced following contrast medium administration, and that oxygenation can suppress the reduction in PaO<sub>2</sub> levels. Although isotonic saline hydration maintains renal plasma flow, when used alone it may be insufficient to resolve systemic and renal ischemia, which may explain the 5% to 10% incidence of CIN associated with the use of isotonic saline hydration.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> In addition, the finding that hyperbaric oxygen treatment improves the glomerular filtration rate in rats with renal ischemic reperfusion injury<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> supports the crucial role of enhanced oxygenation in preserving renal function.</p><p id="p0120">Under physiological conditions, the renal cortex contains the majority of glomeruli and therefore receives most of the renal blood flow, whereas the medulla receives approximately 10%.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> During ischemia, the decrease in blood flow is regional rather than uniform throughout the kidney, and is more prominent in the outer medulla than in the cortex.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The corticomedullary region is most vulnerable to tubular injury, inflammation, and vascular alterations, which can extend cellular injury beyond the initial insult and propagate continued hypoperfusion.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> The fact that patients with unstable hemodynamics (i.e., myocardial infarction and systemic hypoxia due to congestive heart failure) are at high risk for CIN suggests that ischemic acute tubular necrosis or acute cardiorenal syndrome exacerbates contrast-induced renal ischemia.</p><p id="p0125">Despite some negative effects of oxygen such as the potential generation of reactive oxygen species and oxygen-mediated vasoconstriction during ischemia-reperfusion injuries, in cases of acute coronary syndrome, oxygen administration is necessary to protect the patient from myocardial ischemia,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> so the oxygen administration was class IIa according to the American Heart Association guidelines. Thus, supplemental oxygenation may be a simple method to prevent contrast-mediated hypoxic renal injury.</p><p id="p0130">Several strategies have been evaluated for preventing CIN, and the following have demonstrated renoprotective effects and a reduced CIN incidence: hydration with saline solution,<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib29" ref-type="bibr">29</xref> the use of iso-osmolality or low-osmolality contrast agents,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> and application of remote ischemic conditioning.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> However, the efficacy of these strategies remains controversial in patients with severe renal failure undergoing angiographic procedures that require a high volume of contrast medium. Oxygenation treatment via the nasal cannula is minimally invasive and may be used in combination with any of the previously reported methods for CIN prevention. This technique is promising, particularly for high-risk patients, if oxygenation is combined with previously reported pharmacological agents to preserve renal blood flow.</p><p id="p0135">Diabetes mellitus, dehydration, anemia, congestive heart failure, and high contrast volume have been reported as risk factors for CIN.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> In patients with such risk factors, previous reports have indicated that the CIN incidence increased from 7.5% to 26.1% following catheterization.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Contrast medium directly affects endothelium-dependent vasomotion.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Impairment of the renal endothelium results in decreased vasodilation and further enhances regional hypoxia.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Defective endothelial-dependent vasodilation is characteristic of diabetes mellitus,<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> hypertension,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> and heart failure.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Hydration alone is insufficient to prevent CIN under these conditions, which further emphasizes the importance of sufficient renal perfusion in high-risk patients. In the present study, the physician who performed catheterization was aware of the patients&#x02019; renal function before the procedure and therefore used a reduced contrast volume in patients with impaired renal function than in patients with normal renal function, which may explain why contrast volume was not a predictor of CIN in our study.</p><p id="p0140">In our study population, oxygenation treatment effectively decreased the risk of CIN (1% vs. 8%) among patients with an eGFR&#x000a0;&#x0003c; 60 ml/min per 1.73 m<sup>2</sup>. Therefore, this approach may benefit patients with mild CKD. Diabetes mellitus was not associated with CIN in our study cohort. This discrepancy between the results of this study and others might be caused by differences in baseline renal function. Thus, in our patients, the baseline CKD was mild, and in other studies, the baseline CKD was more severe.</p><sec id="sec3.1"><title>Study Limitations</title><p id="p0145">First, our cohort of elective cases with stable hemodynamics represents a population that has a relatively low risk of developing CIN. The optimal preventive threshold of oxygenation requires further examination, particularly in hemodynamically unstable patients or those with acute coronary syndrome, who are highly susceptible to CIN despite the routine use of oxygenation. On the other hand, the AVOID trial<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> showed no benefit of oxygen in MI and in fact, the size of the MI was larger in oxygenation group than in the room air group. Therefore, we must consider these aspects before applying our treatment method to patients with acute coronary syndrome. Second, for practical reasons, oxygen administration was terminated at the end of the procedure. Prolonged oxygenation may be effective in patients with critical renal dysfunction in whom the elimination of contrast medium is delayed. Nevertheless, the observed CIN incidence of 1% using our oxygen protocol appears to be promising for patients with mild CKD in the elective setting. Therefore, it is necessary to investigate patients who are at higher risk for CIN, such as those who receive a high volume of contrast medium or who have more severe CKD, so that the protocol can be adapted for patients with more severe CKD. Third, postprocedural creatinine levels were evaluated only 48 hours after contrast exposure, and because creatinine levels typically peak 3 to 5 days after contrast medium administration, we cannot exclude the possibility that oxygenation merely delayed the development of contrast-induced renal dysfunction. Fourth, our study did not include any novel biomarkers of kidney damage, nor did we capture other urinary measures such as proteinuria or urine volume. Fifth, our study presents only initial findings, and additional research is required to establish the benefit of oxygen before treatment.</p><p id="p0150">This was an open-label study. Although the outcomes were objective measurements of serum creatinine changes, the open-label study may affect patient bias somewhat in this case. Therefore, a single-blinded study is needed to reduce bias, such as by using a nasal delivery device to administer room air to a control group.</p><p id="p0155">Finally, the present study was conducted at a single center, and the number of patients reaching the primary endpoint (CIN incidence) was small. Although univariate analyses identified the absence of oxygenation treatment as significant in predicting CIN incidence, our study may have been inadequate to support multivariate testing. However, it does provide some interesting preliminary data. Additional factors predictive of CIN should be evaluated in a larger study population. A large multicenter study is also needed to evaluate the safety and preventive effects of oxygen in the emergency setting and among patients with acute coronary syndrome, congestive heart failure, diabetes mellitus, and stage IV or higher CKD, who were excluded from the present study.</p><p id="p0160">In conclusion, the addition of oxygenation treatment to conventional isotonic saline hydration decreased the CIN incidence in patients with impaired renal function undergoing elective cardiovascular angiography and PCI. This finding adds to existing data suggesting the importance of renal hypoxia in the pathogenesis of CIN. The benefit of this simple and minimally invasive method was demonstrated among patients with mild CKD.</p></sec></sec><sec id="sec4"><title>Disclosure</title><p id="p0165">All the authors declared no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Rihal</surname><given-names>C.S.</given-names></name><name><surname>Textor</surname><given-names>S.C.</given-names></name><name><surname>Grill</surname><given-names>D.E.</given-names></name></person-group><article-title>Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention</article-title><source>Circulation</source><volume>105</volume><year>2002</year><fpage>2259</fpage><lpage>2264</lpage><pub-id pub-id-type="pmid">12010907</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Cerda</surname><given-names>J.</given-names></name><name><surname>Lameire</surname><given-names>N.</given-names></name><name><surname>Eggers</surname><given-names>P.</given-names></name></person-group><article-title>Epidemiology of acute kidney injury</article-title><source>Clin J Am Soc Nephrol</source><volume>3</volume><year>2008</year><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">18216347</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>P.A.</given-names></name><name><surname>Wolyn</surname><given-names>R.</given-names></name><name><surname>Rocher</surname><given-names>L.L.</given-names></name></person-group><article-title>Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality</article-title><source>Am J Med</source><volume>103</volume><year>1997</year><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">9375704</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R.</given-names></name><name><surname>Aymong</surname><given-names>E.D.</given-names></name><name><surname>Nikolsky</surname><given-names>E.</given-names></name></person-group><article-title>A&#x000a0;simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>44</volume><year>2004</year><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">15464318</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>C.</given-names></name><name><surname>Buerkle</surname><given-names>G.</given-names></name><name><surname>Buettner</surname><given-names>H.J.</given-names></name></person-group><article-title>Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty</article-title><source>Arch Intern Med</source><volume>162</volume><year>2002</year><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">11822926</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>I.</given-names></name><name><surname>Matetzky</surname><given-names>S.</given-names></name></person-group><article-title>Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies</article-title><source>CMAJ</source><volume>172</volume><year>2005</year><fpage>1461</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">15911862</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K.</given-names></name><name><surname>Whittaker</surname><given-names>P.</given-names></name></person-group><article-title>Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities</article-title><source>J&#x000a0;Cardiovasc Pharmacol Ther</source><volume>16</volume><year>2011</year><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">21821525</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Heyman</surname><given-names>S.N.</given-names></name><name><surname>Brezis</surname><given-names>M.</given-names></name><name><surname>Epstein</surname><given-names>F.H.</given-names></name></person-group><article-title>Early renal medullary hypoxic injury from radiocontrast and indomethacin</article-title><source>Kidney Int</source><volume>40</volume><year>1991</year><fpage>632</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">1745012</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>P.</given-names></name><name><surname>Przyklenk</surname><given-names>K.</given-names></name></person-group><article-title>Remote-conditioning ischemia provides a potential approach to mitigate contrast medium-induced reduction in kidney function: a retrospective observational cohort study</article-title><source>Cardiology</source><volume>119</volume><year>2011</year><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">21952203</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Sekiguchi</surname><given-names>H.</given-names></name><name><surname>Ajiro</surname><given-names>Y.</given-names></name><name><surname>Uchida</surname><given-names>Y.</given-names></name></person-group><article-title>Oxygen preconditioning prevents contrast-induced nephropathy (OPtion CIN Study)</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>62</volume><year>2013</year><fpage>162</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">23643590</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Lameire</surname><given-names>N.</given-names></name><name><surname>Adam</surname><given-names>A.</given-names></name><name><surname>Becker</surname><given-names>C.R.</given-names></name></person-group><article-title>Baseline renal function screening</article-title><source>Am J Cardiol</source><volume>98</volume><year>2006</year><fpage>21K</fpage><lpage>26K</lpage></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>E.</given-names></name><name><surname>Horio</surname><given-names>M.</given-names></name><name><surname>Nitta</surname><given-names>K.</given-names></name></person-group><article-title>Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease</article-title><source>Clin Exp Nephrol</source><volume>11</volume><year>2007</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17384997</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>P.A.</given-names></name><name><surname>Adam</surname><given-names>A.</given-names></name><name><surname>Becker</surname><given-names>C.R.</given-names></name><collab>CIN Consensus Working Panel</collab></person-group><article-title>Risk prediction of contrast-induced nephropathy</article-title><source>Am J Cardiol</source><volume>98</volume><year>2006</year><fpage>27K</fpage><lpage>36K</lpage></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>R.</given-names></name><name><surname>Werner</surname><given-names>C.</given-names></name><name><surname>Mann</surname><given-names>D.</given-names></name></person-group><article-title>Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents</article-title><source>N&#x000a0;Engl J Med</source><volume>331</volume><year>1994</year><fpage>1416</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">7969280</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Tumlin</surname><given-names>J.</given-names></name><name><surname>Stacul</surname><given-names>F.</given-names></name><name><surname>Adam</surname><given-names>A.</given-names></name></person-group><article-title>Pathophysiology of contrast-induced nephropathy</article-title><source>Am J Cardiol</source><volume>98</volume><year>2006</year><fpage>14K</fpage><lpage>20K</lpage><pub-id pub-id-type="pmid">16784912</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Maeder</surname><given-names>M.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Fehr</surname><given-names>T.</given-names></name></person-group><article-title>Contrast nephropathy: review focusing on prevention</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>44</volume><year>2004</year><fpage>1763</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">15519005</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>J.F.</given-names></name><name><surname>Droz</surname><given-names>D.</given-names></name><name><surname>Noel</surname><given-names>L.H.</given-names></name></person-group><article-title>Tubular nephrotoxicity of water-soluble iodinated contrast media</article-title><source>Invest Radiol</source><volume>15</volume><year>1980</year><fpage>S54</fpage><lpage>S60</lpage><pub-id pub-id-type="pmid">7203949</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Heyman</surname><given-names>S.N.</given-names></name><name><surname>Fuchs</surname><given-names>S.</given-names></name><name><surname>Jaffe</surname><given-names>R.</given-names></name></person-group><article-title>Renal microcirculation and tissue damage during acute ureteral obstruction in the rat: effect of saline infusion, indomethacin and radiocontrast</article-title><source>Kidney Int</source><volume>51</volume><year>1997</year><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">9067896</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="book" id="sref19"><person-group person-group-type="editor"><name><surname>Goldstein</surname><given-names>R.S.</given-names></name><name><surname>Hook</surname><given-names>J.B.</given-names></name></person-group><source>Toxicology of the Kidney</source><edition>2nd ed.</edition><year>1993</year><publisher-name>Raven Press</publisher-name><publisher-loc>New York, NY</publisher-loc></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Katholi</surname><given-names>R.E.</given-names></name><name><surname>Woods</surname><given-names>W.T.</given-names><suffix>Jr.</suffix></name><name><surname>Taylor</surname><given-names>G.J.</given-names></name></person-group><article-title>Oxygen free radicals and contrast nephropathy</article-title><source>Am J Kidney Dis</source><volume>32</volume><year>1998</year><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9669426</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Liss</surname><given-names>P.</given-names></name><name><surname>Nygren</surname><given-names>A.</given-names></name><name><surname>Erikson</surname><given-names>U.</given-names></name></person-group><article-title>Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla</article-title><source>Kidney Int</source><volume>53</volume><year>1998</year><fpage>698</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">9507216</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Heyman</surname><given-names>S.N.</given-names></name><name><surname>Rosenberger</surname><given-names>C.</given-names></name><name><surname>Rosen</surname><given-names>S.</given-names></name></person-group><article-title>Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy</article-title><source>Nephrol Dial Transplant</source><volume>20</volume><issue>suppl 1</issue><year>2005</year><fpage>i6</fpage><lpage>i11</lpage><pub-id pub-id-type="pmid">15705946</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Dussol</surname><given-names>B.</given-names></name><name><surname>Morange</surname><given-names>S.</given-names></name><name><surname>Loundoun</surname><given-names>A.</given-names></name></person-group><article-title>A&#x000a0;randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients</article-title><source>Nephrol Dial Transplant</source><volume>21</volume><year>2006</year><fpage>2120</fpage><lpage>2126</lpage><pub-id pub-id-type="pmid">16611682</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>I.</given-names></name><name><surname>Abassi</surname><given-names>Z.</given-names></name><name><surname>Milman</surname><given-names>F.</given-names></name></person-group><article-title>Hyperbaric oxygen treatment improves GFR in rats with ischaemia/reperfusion renal injury: a possible role for the antioxidant/oxidant balance in the ischaemic kidney</article-title><source>Nephrol Dial Transplant</source><volume>24</volume><year>2009</year><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">18799609</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>W.M.</given-names></name><name><surname>Beekhuis</surname><given-names>H.</given-names></name><name><surname>de Bruin</surname><given-names>R.</given-names></name></person-group><article-title>Noninvasive measurement of intrarenal blood flow distribution: kinetic model of renal <sup>123</sup>I-hippuran handling</article-title><source>Am J Physiol</source><volume>269</volume><year>1995</year><fpage>F571</fpage><lpage>F580</lpage><pub-id pub-id-type="pmid">7485544</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Dagher</surname><given-names>P.C.</given-names></name><name><surname>Herget-Rosenthal</surname><given-names>S.</given-names></name><name><surname>Ruehm</surname><given-names>S.G.</given-names></name></person-group><article-title>Newly developed techniques to study and diagnose acute renal failure</article-title><source>J&#x000a0;Am Soc Nephrol</source><volume>14</volume><year>2003</year><fpage>2188</fpage><lpage>2198</lpage><pub-id pub-id-type="pmid">12874475</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>T.A.</given-names></name></person-group><article-title>Alteration of microvascular permeability in acute kidney injury</article-title><source>Microvasc Res</source><volume>77</volume><year>2009</year><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18938184</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Fillmore</surname><given-names>S.J.</given-names></name><name><surname>Shapiro</surname><given-names>M.</given-names></name><name><surname>Killip</surname><given-names>T.</given-names></name></person-group><article-title>Arterial oxygen tension in acute myocardial infarction. Serial analysis of the clinical state and blood gas changes</article-title><source>Am Heart J</source><volume>79</volume><year>1970</year><fpage>620</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">5444451</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>H.S.</given-names></name><name><surname>Moore</surname><given-names>H.</given-names></name><name><surname>Nasr</surname><given-names>S.</given-names></name></person-group><article-title>A&#x000a0;randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity</article-title><source>Nephron Clin Pract</source><volume>93</volume><year>2003</year><fpage>C29</fpage><lpage>C34</lpage><pub-id pub-id-type="pmid">12411756</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>M.C.</given-names></name><name><surname>Haberle</surname><given-names>L.</given-names></name><name><surname>Muller</surname><given-names>V.</given-names></name></person-group><article-title>Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials</article-title><source>Radiology</source><volume>250</volume><year>2009</year><fpage>68</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">19092091</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Klause</surname><given-names>N.</given-names></name><name><surname>Arendt</surname><given-names>T.</given-names></name><name><surname>Lins</surname><given-names>M.</given-names></name></person-group><article-title>Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man</article-title><source>Adv Exp Med Biol</source><volume>454</volume><year>1998</year><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">9889896</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="book" id="sref32"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>B.M.</given-names></name><name><surname>Rector</surname><given-names>F.C.</given-names><suffix>Jr.</suffix></name></person-group><chapter-title>The Kidney</chapter-title><edition>4th edition</edition><year>1991</year><publisher-name>WB Saunders</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Calver</surname><given-names>A.</given-names></name><name><surname>Collier</surname><given-names>J.</given-names></name><name><surname>Vallance</surname><given-names>P.</given-names></name></person-group><article-title>Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes</article-title><source>J&#x000a0;Clin Invest</source><volume>90</volume><year>1992</year><fpage>2548</fpage><lpage>2554</lpage><pub-id pub-id-type="pmid">1469103</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Panza</surname><given-names>J.A.</given-names></name><name><surname>Quyyumi</surname><given-names>A.A.</given-names></name><name><surname>Brush</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension</article-title><source>N&#x000a0;Engl J Med</source><volume>323</volume><year>1990</year><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">2355955</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>S.H.</given-names></name><name><surname>Rector</surname><given-names>T.S.</given-names></name><name><surname>Bank</surname><given-names>A.J.</given-names></name></person-group><article-title>Endothelium-dependent vasodilation is attenuated in patients with heart failure</article-title><source>Circulation</source><volume>84</volume><year>1991</year><fpage>1589</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">1914099</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Stub</surname><given-names>D.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Bernard</surname><given-names>S.</given-names></name></person-group><article-title>Air versus oxygen in ST-segment-elevation myocardial infarction</article-title><source>Circulation.</source><volume>131</volume><year>2015</year><fpage>2143</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">26002889</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>The study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) with the identifier UMIN000007125. The authors thank Editage (<ext-link ext-link-type="uri" xlink:href="http://www.editage.jp" id="intref0010">www.editage.jp</ext-link>) for English language editing.</p><p>This work was supported by funds from the National Hospital Organization Yokohama Medical Center Clinical Research Division, Yokohama, Japan. The sponsors of this study were not involved in the study design, collection, analysis, data interpretation, or writing of this report.</p></ack></back></article>